PLAN B SUMMARY
Plan B® (Levonorgestrel) Tablets, 0.75 mg
Emergency contraceptive tablet. Each Plan B® tablet contains 0.75 mg of a single active steroid ingredient, levonorgestrel [18,19-Dinorpregn-4-en-20-yn-3-one-13-ethyl-17-hydroxy-, (17(alpha))-(-)-], a totally synthetic progestogen.
Plan B® is an emergency contraceptive that can be used to prevent pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the first tablet should be taken as soon as possible within 72 hours of intercourse. The second tablet must be taken 12 hours later.
Media Articles Related to Plan B (Levonorgestrel)
Research reveals more than half of young women who have abortions were using contraception when they fell pregnant
Source: Abortion News From Medical News Today [2014.04.30]
Reproductive health charity Marie Stopes UK has launched the findings of the first research in the UK into the contraceptive use of women aged 16-24 having one or more abortions.
New research shows a statistical significant association between increased LARC usage and reduction in teenage pregnancy and abortion rates in England
Source: Abortion News From Medical News Today [2014.11.27]
New findings, published in the International Journal of Women's Health, show increased long-acting reversible contraception (LARC) usage in England was significantly associated with decreased...
Free birth control reduces teen pregnancies and abortions
Source: Abortion News From Medical News Today [2014.10.03]
Teens who received free contraception and were educated about the pros and cons of various birth control methods were dramatically less likely to get pregnant, give birth or get an abortion compared...
Published Studies Related to Plan B (Levonorgestrel)
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90
mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual
and premenstrual syndrome (PMS)... CONCLUSIONS: These data, although not consistent, indicate that continuous LNG/EE
Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. [2011.11.29]
BACKGROUND: This study evaluated the ethinyl estradiol (EE) and levonorgestrel (LNG) pharmacokinetic profiles of AG200-15, a transdermal contraceptive delivery system, compared with a combination oral contraceptive (COC) containing EE 35 mcg and norgestimate 250 mcg... CONCLUSIONS: EE and LNG daily exposure during AG200-15 treatment was within the range reported for a low-dose COC. The daily EE dose with AG 200-15 was equivalent to a 30-mcg COC and was safe and well tolerated. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. [2011.09.24]
OBJECTIVE: The purpose of this study was to evaluate whether oral naproxen or transdermal estradiol decreases bleeding and spotting in women who are initiating the levonorgestrel-releasing intrauterine system... CONCLUSION: The administration of naproxen resulted in a reduction in bleeding and spotting days compared with placebo. Copyright A(c) 2011 Mosby, Inc. All rights reserved.
Immediate versus delayed insertion of the levonorgestrel-releasing intrauterine device following dilation and evacuation: a randomized controlled trial. [2011.09.13]
BACKGROUND: The study was conducted to compare 6-month usage of the levonorgestrel-releasing intrauterine device (LNG-IUD) when placed immediately or 3 to 6 weeks after dilation and evacuation (D&E) procedure... CONCLUSION: Significantly more participants had the LNG-IUD placed in the immediate insertion group compared with the delayed insertion group. Given the low risk of complications, immediate post-D&E insertion of the LNG-IUD should be offered, especially for populations that may have difficulty returning for follow-up. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Efficacy and safety of a levonorgestrel enteric-coated tablet as an over-the-counter drug for emergency contraception: a Phase IV clinical trial. [2011.09]
BACKGROUND: An enteric-coated levonorgestrel emergency contraceptive pill (E-LNG-ECP) is an improved formulation, in terms of side effects, which both dissolves and is absorbed in the intestine. Our aim was to evaluate the efficacy and safety of E-LNG-ECP as an over-the-counter (OTC) drug for emergency contraception (EC) in Chinese women... CONCLUSIONS: The study found that E-LNG-ECP was effective, safe and well tolerated as an OTC drug. However, an randomized controlled trial should be performed to compare standard LNG tablets with E-LNG-ECP.
Clinical Trials Related to Plan B (Levonorgestrel)
Medifast 5 & 1 Plan [Not yet recruiting]
The purpose of this study is to compare the effectiveness of the Medifast 5 & 1 Plan to a
food-based, reduced-energy diet plan. The study will be conducted over 52 weeks, including a
26-week weight-loss phase and a 26-week weight-maintenance phase. 120 participants will be
enrolled, with 60 randomized to the Medifast 5 & 1 Plan and 60 randomized to food-based,
reduced-energy diet plan. Multiple measures will be performed at baseline, 26 weeks, and 52
weeks, including anthropometry, body composition, blood pressure, blood assays, and appetite
Planned CORR: Planned Care for Obesity and Risk Reduction [Recruiting]
The researchers propose a randomized controlled trial to evaluate how well an intervention,
Planned Care for Obesity & Risk Reduction (Planned CORR), supports primary care treatment of
obesity in adults with at least one cardiovascular risk factor (CVRF).
Comparing Asthma Action Plans for Pediatric Asthma [Recruiting]
The purpose of this study is to evaluate and compare the relative effectiveness of two
asthma action plans (pictorial versus written) in terms of asthma action plan knowledge,
medication use, and family satisfaction with asthma education.
The Electronic Asthma Action Plan System for Implementation in Primary Care [Recruiting]
Asthma is a common and potentially fatal chronic disease. An asthma action plan (AAP) is a
written plan produced by a physician for a patient with asthma, to provide education and
guidelines for self-management of worsening asthma symptoms. Studies have shown that AAPs
effectively improve asthma control, but physicians fail to provide AAPs due to lack of time
and adequate skills. The investigators propose to develop a computerized tool that will
automatically generate an electronic version of the AAP, based on patient responses to
questions about their current asthma control. The investigators hope that this system will
eliminate the barriers that physicians face in delivery of an AAP and will increase the
frequency with which physicians are able to deliver AAPs to patients with asthma. The
objectives of the study are to determine the impact of an electronic asthma action plan
system on asthma action plan delivery by primary care physicians, to determine the impact of
an electronic asthma action plan system on patient hospitalisations, emergency room (ER)
visits, unscheduled visits to the doctor, total visits to the doctor, days off work or
school, nocturnal asthma symptoms, daytime asthma symptoms, daytime rescue puffer use, and
quality of life , and to measure physicians' perceptions of and satisfaction with the
Specific Care and Assistance Plan for Alzheimer's Disease [Completed]
The main objective of this work is to assess the feasibility and efficacy of a specific Care
and Assistance Plan for Alzheimer's disease (PLASA). The main outcome measure selected is
incapacity in carrying out the basic activities of daily living, evaluated by the ADCS-ADL
The PLASA was developed by a working group appointed by the Direction Générale de la Santé as
part of the government programme of action on Alzheimer's disease (October 2001, Ministère de
l'Emploi et de la Solidarité).
Reports of Suspected Plan B (Levonorgestrel) Side Effects
Abortion Spontaneous (5),
Vaginal Haemorrhage (3),
Pulmonary Embolism (2),
Unintended Pregnancy (2),
Menstruation Irregular (2),
Blighted Ovum (2),
Muscle Spasms (2),
Maternal Exposure Before Pregnancy (2),
Asthma (1), more >>
Page last updated: 2014-11-27